



10th Anniversary of Biomedicines—Advances in Prostate Cancer: Science Discovery, Drug Resistance, Biomarkers, and Beyond

Guest Editor:

Prof. Dr. Shu-Pin Huang

Department of Urology, Faculty
of Medicine, College of Medicine,
Kaohsiung Medical University,
Kaohsiung, Taiwan

Deadline for manuscript
submissions:

closed (31 May 2023)

Message from the Guest Editor

Prostate cancer is the second most common cancer affecting men worldwide, with 1.4 million new cases in 2020. The etiology of prostate cancer remains largely unknown; in addition to aging and ethnicity, genetic and environmental factors are believed to contribute to the development of prostate cancer. Prostate cancer is characterized as molecularly heterogeneous, and its natural history is highly variable, which leads to different treatment modality from active surveillance to aggressive treatment. Understanding these biological alterations behind is crucial in determining the course of the disease and providing a guide for therapy. Although most prostate cancers initially respond to androgen deprivation therapy (ADT), they gradually develop resistance and progress to castration-resistant prostate cancer (CRPC), which eventually becomes lethal. Understanding the mechanisms of CRPC will help us to develop novel treatment strategies and predict drug response toward precision medicine. We welcome multidisciplinary research articles that will enhance our knowledge on prostate cancer.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)